Stony Brook Hires Cancer Immunology Researcher Min-Guk Cho
Min-Guk Cho joined Stony Brook University's Renaissance School of Medicine to study immune signaling and triple negative breast cancer.
Updated on Nov. 21, 2026 in Diseases

Stony Brook University has hired Min-Guk Cho as an Assistant Professor in the Department of Pharmacological Sciences at the Renaissance School of Medicine, where he arrived in July. Cho studies the cGAS-STING pathway, part of the innate immune system, and is initiating a research lab focused on triple negative breast cancer.
Why it matters
Triple negative breast cancer accounts for about 10 to 15 percent of breast cancer cases, and Cho's work aims to clarify how the cGAS-STING pathway links DNA damage to immune responses. For New York residents, the hire adds research capacity at Stony Brook's Cancer Center.
Triple negative breast cancer accounts for roughly 10 to 15 percent of breast cancer cases, a share the new lab will focus on. Cho has not yet reported results, and his stated goal of identifying new cGAS activation regulators over the next one to two years remains unmet.
The players
Stony Brook University
Stony Brook University is a public research university in Stony Brook, New York, and part of the State University of New York system, home to the Renaissance School of Medicine and its Cancer Center.
Kenneth Shroyer
Kenneth Shroyer is chair of the Department of Pathology at Stony Brook University, who met with Cho individually and encouraged him to join the university.
The details
Cho's lab will use breast cancer mouse models while also exploring organoid development, and will run genetic screens to find regulators of the cGAS-STING pathway and study their molecular mechanisms. The lab includes master's student Eva Atmaca, undergraduates Eshaal Irfan, Tasmina Mahmud, Soyi Kwon and Mae Suebsanguan, and instructor Ju-Hyun Ahn. Cho does not provide clinical care or diagnose patients.
Timeline
July: Cho arrived at Stony Brook University.
Next one to two years: Cho hopes to identify new regulators of cGAS activation.
Next few years: Cho expects to expand collaborative research activities.
Health Landscape
Research on the cGAS-STING innate immune pathway has grown as scientists seek to understand how DNA damage triggers immune responses in cancer. Cho's appointment adds a researcher focused on that pathway in triple negative breast cancer at a New York institution.
Cho does not provide clinical care or diagnose patients, so the hire does not change treatment access for patients in the near term. Its effect will come through research that may inform future therapies for triple negative breast cancer.
The takeaway
Basic research into immune pathways like cGAS-STING can take years to reach patients, so new faculty hires like Cho's matter for long-term progress. Readers interested in cancer research can follow how such labs publish their findings.
Further reading
Explore more cancer research coverage for context on how immune signaling is being studied across New York institutions.
Source note: This article includes information reported by TBR News Media.






